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Background: Cough-variant asthma (CVA) and cough-predominant asthma (CPA) are the major causes of
persistent cough in Japan. The utility of fractional exhaled nitric oxide (FeNO) measurement in the dif-
ferential diagnosis of persistent cough has been reported, but the inﬂuence of atopic status, which is
associated with higher FeNO levels, on the diagnostic utility of FeNO has been unknown.
Methods: We retrospectively analyzed 105 non-smoking patients with prolonged and chronic cough that
were not treated with corticosteroids and anti-leukotrienes.
Results: CPA was diagnosed in 37 patients, CVA in 40, and non-asthmatic cough (NAC) in 28. FeNO levels
were signiﬁcantly higher in the CPA [35.8 (7.0e317.9) ppb] and CVA [24.9 (3.1e156.0) ppb] groups than in
the NAC group [18.2 (6.9e49.0) ppb] (p < 0.01 by KruskaleWallis test). The optimal cut-off for dis-
tinguishing asthmatic cough (AC; CPA and CVA) from NAC was 29.2 ppb [area under the curve (AUC) 0.74,
p < 0.01]. Ninety-one percent of subjects with FeNO levels 29.2 ppb had AC. Meanwhile, 40% of AC
patients had FeNO levels <29.2 ppb. Stratiﬁed cut-off levels were 31.1 ppb (AUC 0.83) in atopic subjects
vs. 19.9 ppb (AUC 0.65) in non-atopic subjects (p ¼ 0.03 for AUC).
Conclusions: Although high FeNO levels suggested the existence of AC, lower FeNO levels had limited
diagnostic signiﬁcance. Atopic status affects the utility of FeNO levels in the differential diagnosis of
prolonged and chronic cough.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cough is one of the most common symptoms for which patients
seek medical attention.1 Almost all guidelines have consistently
classiﬁed cough into three categories according to its duration:
acute cough lasting for less than 3 weeks, prolonged or subacute
cough lasting for a period of 3e8 weeks, and chronic cough per-
sisting for more than 8 weeks.2,3 Generally, as cough durationtory Medicine, Allergy and
School of Medical Sciences, 1
7-8602, Japan.
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rgology. Production and hosting by Else
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6), http://dx.doi.org/10.1016/becomes longer, the prevalence of non-infectious causes of cough
becomes higher.2 In Japan, the most prevalent causative diseases of
isolated chronic cough have been reported to be cough-variant
asthma (CVA), atopic cough, and sinobronchial syndrome, fol-
lowed by gastroesophageal reﬂux disease (GERD).4,5 A recent
multicenter study involving isolated cough patients and also those
coughed predominantly but complicated by wheeze/dyspnea
revealed a high prevalence of CVA and cough-predominant asthma
(CPA), accounting for more than 70% of both prolonged and chronic
cough.1
Fractional exhaled nitric oxide (FeNO) measurement is consid-
ered a useful surrogate marker of Th2-driven airway inﬂamma-
tion.6,7 FeNO levels correlate with sputum eosinophil count,8 and
higher FeNO levels have been reported in asthmatic patientsvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
nal exhaled nitric oxide in prolonged and chronic cough according to
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Table 1
Etiology of prolonged and chronic cough in our study population (N ¼ 105).
Diagnosis Number (%)
Asthmatic cough Cough-predominant asthmay 37 (35%) 77 (73.3%)
Cough-variant asthmaz 40 (38%)
Non-asthmatic cough Gastroesophageal reﬂux disease 14 (13%) 28 (26.7%)
Sinobronchial syndrome 8 (8%)
Post-infectious cough 4 (4%)
Atopic cough 2 (2%)
y 32 isolated, 4 with concomitant gastroesophageal reﬂux disease, 1 with
concomitant sinobronchial syndrome.
z 30 isolated, 10 with concomitant gastroesophageal reﬂux disease.
T. Asano et al. / Allergology International xxx (2016) 1e72compared with non-asthmatic subjects.9,10 Since FeNO levels are
affected by the presence of allergic rhinitis and smoking, Matsu-
naga et al. proposed four cut-off levels for FeNO, stratiﬁed by these
two factors, to discriminate asthma from non-asthma.11
Atopy, which is common in CPA and CVA,8,12 is also known as
one of the factors that affect FeNO levels.13,14 Although the utility of
FeNO measurements in the differential diagnosis of prolonged or
chronic cough has been reported,12,15e18 no study has taken into
account the atopic status, which may affect the results. In the
present study, we investigated the utility of FeNO measurement in
distinguishing asthmatic cough from non-asthmatic cough, in
consideration of the atopic status.
Methods
Subjects
We retrospectively analyzed consecutive patients with pro-
longed and chronic cough lasting for more than 3 weeks. These
patients were newly referred to our asthma and chronic cough
clinic at Nagoya City University (Nagoya, Japan) and underwent
FeNO measurements, from March 2013 to April 2015. Exclusion
criteria were 1) prior treatment with inhaled corticosteroids or
anti-leukotriene agents; 2) abnormal chest radiograph ﬁndings
that may explain the cough; 3) fever, blood-stained sputum, or
active respiratory infection; and 4) current smokers or former
smokers of more than ﬁve pack-years or those who quited smoking
within for less than 3 months preceding the study. Patients with
shortness of breath or wheezing and those with multiple causes of
cough were included, as in our previous study.1 The study was
approved by the ethics committee of Nagoya City University Hos-
pital (44-12-0004).
Cough-predominant asthma (CPA) was diagnosed when pa-
tients had cough as the predominant symptoms while together
with wheeze and/or dyspnea, and either positive airway hyper-
responsiveness to methacholine2 assessed by the continuous
methacholine inhalation method (Astograph®; Chest, Tokyo,
Japan),19 or reversible airﬂow obstruction.20,21 A diagnosis of CVA
was based on an isolated cough, which was relieved by b2-agonists,
and positive airway hyperresponsiveness.2 Patients with CPA and
CVA were combined into the asthmatic cough (AC) group for
further analysis.
A diagnosis of non-asthmatic cough (NAC) was made as follows.
GERD-related cough was suspected by the presence of 1) classic
reﬂux symptoms of heartburn, indigestion, chest discomfort, throat
clearing, dysphonia, dysphagia, and belching and/or 2) typical
characteristics of cough that is triggered by phonation, rising, lying,
eating, and intake of certain food.22 A diagnosis was conﬁrmed
when cough was relieved by proton pump inhibitors with or
without gastrointestinal prokinetic agents.22,23
Post-infectious coughwas diagnosed when cough was preceded
by an acute respiratory tract infection that was not complicated by
pneumonia and eventually resolved spontaneously.2 Sinobronchial
syndrome was diagnosed based on ﬁndings of chronic sinusitis on
sinus imaging and improvement of cough and symptoms related to
chronic sinusitis with macrolide antibiotics.2,24 Atopic cough was
diagnosed based on the presence of atopic status and response of
coughing to histamine H1 receptor antagonist, but not to inhaled
b2-agonist.2,25
Overlapping cases of AC and various causes of non-asthmatic
cough (NAC) were categorized as AC subgroups (CPA or CVA).
As previously described, the biological diagnosis of atopy was
made by positive speciﬁc immunoglobulin E (IgE) against at least
one prevalent allergen (>0.70 kU/l), regardless of the level of total
IgE.20 These allergens included house dust mite, mixed JapanesePlease cite this article in press as: AsanoT, et al., Diagnostic utility of fracti
atopic status, Allergology International (2016), http://dx.doi.org/10.1016/cedar pollen, graminea pollens, mixed weed pollen (ragweed,
mugwort, goldenrod, dandelion, and oxeye daisy), Trichophyton,
mixed molds (Candida, Penicillium, Alternaria, Aspergillus, Helmin-
thosporium, and Cladosporium), cat dander, and dog dander.26
Measurement of study variables
Spirometry was measured with Chestac-8900® (Chest; Tokyo,
Japan), according to the American Thoracic Society/European Res-
piratory Society recommendation.27
FeNO measurement
FeNO was measured by Sievers NOA280i chemiluminescence
analyzer (GE Analytical Instruments; Boulder, Colorado, USA) at a
ﬂow rate of 50 ml/s, according to ERS/ATS recommendations.6
Statistical analysis
Statistical analysis was performed with JMP10 Start Statics (SAS
Institute Inc., Cary, North Carolina, USA). Normally distributed
variables were described as mean (SD) and non-normally distrib-
uted variables were described as median (range). Comparison of
three groups was made using Chi-square test, ANOVA followed by
TukeyeKramer test, or KruskaleWallis analysis followed by Steel-
eDwass analysis, as appropriate. Comparison of two groups was
made using ManneWhitney U test. The cut-off value for dis-
tinguishing AC from NAC was determined by receiver operating
characteristic (ROC) curve analysis. Comparison of area under the
curve (AUC) of ROC between atopic subjects and non-atopic sub-
jects was made by DeLong's test.
Univariate analysis was done to evaluate the patient character-
istics that were signiﬁcantly associated with higher FeNO levels;
speciﬁcally, these factors were age, sex, body mass index (BMI),
former smoking status (%), cough duration, diagnosis, atopy, blood
eosinophil (/mm3), total serum IgE (IU/ml), and % predicted forced
expiratory volume in 1 s (FEV1), FEV1/forced vital capacity (FVC),
and forced expiratory ﬂow between 25 and 75% (FEF25e75). Vari-
ables that had a p value of <0.10 in the univariate analysis were
included in the multivariate logistic regression analysis to evaluate
which one predict higher FeNO levels (more than the cut-off value
calculated by the ROC curve analysis). Correlations between FeNO
levels and blood eosinophil count and serum IgE levels were
analyzed by Spearman's rank correlation test.
Results
A total of 105 patients were analyzed; ﬁnal diagnosis was CPA in
37 (35.2%); CVA in 40 (38.1%); and NAC in 28 (26.7%), including 14
patients with GERD (Table 1). Comparison of the patient in the CPA,
CVA, and NA groups is shown in Table 2. The CPA group hadonal exhaled nitric oxide in prolonged and chronic cough according to
j.alit.2016.08.015
Table 2
Comparison of patients with prolonged and chronic cough according to etiology (N ¼ 105).
CPA CVA NAC p
Number 37 40 28
Age (year) 51.7 (17.3) 48.2 (19.4) 43.6 (18.8) 0.23
Male/female (n) 12/25 16/24 10/18 0.79
BMI (kg/m2) 22.0 (3.5) 22.2 (4.2) 22.0 (4.1) 0.98
Smoking status (former/never) 6/31 3/37 3/25 0.48
Cough duration (month) 17.0 (11.3) 25.0 (9.6) 27.1 (11.5) 0.80
Atopy (n [%]) 25 [68] 20 [50] 12 [43] 0.07
Blood eosinophil (/mm3) 301.7 (246.4) 159.9 (105.3) 140.7 (86.9) 0.004y
Total serum IgE (IU/ml) 131.0 (6.4e5010.0) 49.4 (5e1210.0) 58.5 (6.4e758.0) 0.15
FVC (% predicted) 101.5 (17.4) 99.0 (17.6) 103.0 (13.8) 0.61
FEV1 (% predicted) 93.1 (17.9) 97.6 (16.2) 101.3 (15.9) 0.15
FEV1/FVC (%) 75.7 (10.8) 81.7 (6.1) 84.9 (7.9) 0.0001z
FEF25e75 (% predicted) 63.2 (29.7) 76.1 (26.8) 83.3 (22.4) 0.01x
Data are described as mean (SD) or median (range), unless otherwise stated.
CPA, cough-predominant asthma; CVA, cough variant asthma; NAC, non-asthmatic cough; BMI, body mass index; IgE, immunoglobulin E; IU, international unit; FEV1, forced
expiratory volume in one second; FVC, forced vital capacity; FEF25e75, forced expiratory ﬂow between 25 and 75%.
y CPA vs. CVA: p ¼ 0.002; CPA vs. NAC: p ¼ 0.002.
z CPA vs. CVA: p ¼ 0.008; CPA vs. NAC: p ¼ 0.0001.
x CPA vs. NAC: p ¼ 0.01.
T. Asano et al. / Allergology International xxx (2016) 1e7 3signiﬁcantly higher blood eosinophil count and lower lung function
measures (FEV1/FVC, FEF25e75) compared with the other two
groups. The proportion of atopic subjects was 68% in CPA, 50% in
CVA, and 43% in NA (p ¼ 0.07). No signiﬁcant differences were
found in the other indices.Fig. 1. Comparison of FeNO levels in the three groups of patients with prolonged and chron
compared with those in the NAC group (p < 0.0001, by KruskaleWallis test). In the CPA a
subjects (p < 0.05, by ManneWhitney U test). This ﬁgure is presented in logarithmic
predominant asthma; CVA, cough-variant asthma; NAC, non-asthmatic cough.
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atopic status, Allergology International (2016), http://dx.doi.org/10.1016/FeNO levels were signiﬁcantly higher in the CPA [35.8
(9.7e317.9) ppb] and CVA [27.6 (3.1e156.0) ppb] groups than in the
NAC group [18.3 (6.9e35.4) ppb] (Fig. 1A). Signiﬁcant differences in
FeNO levels were also found between the CPA and CVA groups. The
FeNO levels in the NAC group were 18.1 (7.8e35.4) ppb for GERD,ic cough (N ¼ 105). FeNO levels in the CPA and CVA groups were signiﬁcantly higher
nd NAC groups, atopic subjects had signiﬁcantly higher FeNO levels than non-atopic
scales. FeNO, fractional exhaled nitric oxide; ppb, parts per billion; CPA, cough-
nal exhaled nitric oxide in prolonged and chronic cough according to
j.alit.2016.08.015
Fig. 2. Receiver operating characteristic curve analysis for distinguishing AC from NAC as a cause of prolonged and chronic cough (N ¼ 105). The overall optimal cut-off value was
29.2 ppb (AUC, 0.74). The cut-off value for atopic subjects was higher (31.1 ppb) than that for non-atopic subjects (19.9 ppb). AC, asthmatic cough; NAC, non-asthmatic cough; AUC,
area under the curve; ppb, parts per billion.
T. Asano et al. / Allergology International xxx (2016) 1e7417.9 (9.2e35.4) ppb for SBS, 17.1 (6.9e33.4) ppb for PIC, and 19.2
(18.2e20.1) for atopic cough. Similarly, FeNO levels were signiﬁ-
cantly higher in the combined AC group [33.2 (3.1e317.9) ppb] than
in the NAC group (p < 0.0001) (Fig. 1B). In the evaluation of FeNO
levels based on atopic status, atopic subjects had signiﬁcantly
higher FeNO levels than non-atopic subjects in the CPA, NAC, and
AC groups, but not in the CVA group (Fig. 1).
The overall diagnostic utility of FeNO levels to distinguish AC
from NAC was examined by ROC curve analysis, which revealedTable 3
Univariate analysis of factors affecting patients with prolonged and chronic cough
according to FeNO levels (N ¼ 105).
FeNO  29.2 ppb FeNO > 29.2 ppb p
Number 56 49
Age (year) 46.3 (18.2) 50.4 (19.1) 0.28
Male/female (n) 17/39 21/28 0.18
BMI (kg/m2) 22.0 ± 3.7 22.2 ± 4.1 0.77
Smoking status (former/never) 6/50 6/43 0.81
Cough duration (month) 5.0 (0.5e480.0) 5.0 (0.2e108.0) 0.41
Diagnosis (AC/NAC) 31/25 46/3 <0.0001
Atopy (n [%]) 21 [38] 35 [71] 0.0005
Blood eosinophil (/mm3) 145.4 (89.3) 284.9 (227.2) 0.0001
Total serum IgE (IU/ml) 49.3 (5.0e758.0) 144.0 (8.4e5010.0) 0.003
FVC (% predicted) 102.2 (14.3) 99.4 (18.9) 0.40
FEV1/FVC 81.8 [7.0] 78.8 [11.0] 0.09
FEF25e75 (% predicted) 75.8 (24.1) 70.8 (31.5) 0.36
Results with borderline signiﬁcance (p < 0.10) are typed in bold.
FeNO, fractional exhaled nitric oxide; ppb, parts per billion; BMI, body mass index;
AC, asthmatic cough; NAC, non-asthmatic cough; IgE, immunoglobulin E; IU, in-
ternational unit; FEV1, forced expiratory volume in one second; FVC, forced vital
capacity, FEF25e75, forced expiratory ﬂow between 25 and 75%.
Please cite this article in press as: AsanoT, et al., Diagnostic utility of fracti
atopic status, Allergology International (2016), http://dx.doi.org/10.1016/29.2 ppb (AUC 0.74) as the optimal cut-off value (Fig. 2). In the
univariate analysis, which compared patient characteristics based
on this cut-off value (high FeNO levels, >29.2 ppb vs. low FeNO
levels, 29.2 ppb), the factors that were identiﬁed to have
borderline signiﬁcant effects on FeNO levels (p < 0.10) were etiol-
ogy of cough (AC/NAC), atopy (%), blood eosinophil (/mm3), total
serum IgE (IU/ml), and FEV1/FVC (Table 3). Among them, blood
eosinophil (/mm3) and total serum IgE (IU/ml) were excluded from
the following multivariate analysis since they were both con-
founding factors for atopy (%). In the multivariate analysis, atopic
status and a diagnosis of AC were identiﬁed as independent factors
associated with higher FeNO levels (Table 4). The ROC curve ana-
lyses based on atopic status revealed different cut-off levels for
FeNO levels: 31.1 ppb for atopic subjects and 19.9 ppb for non-
atopic subjects (Fig. 2). High AUC (0.83) was obtained in atopic
subjects, suggesting a high degree of utility for FeNO measure-
ments. On the contrary, non-atopic subjects had signiﬁcantly
(p ¼ 0.03) lower AUC (0.65) than atopic subjects.Table 4
Multivariate logistic regression models for prediction of FeNO levels in patients with
prolonged and chronic cough (N ¼ 105).
Parameter Odds ratio (95% CI) p
Diagnosis (asthmatic cough) 11.2 (3.3, 52.7) <0.0001
Atopy (n [%]) 3.9 (1.6, 10.0) 0.003
FEV1/FVC (%) 1.0 (0.9, 1.0) 0.99
The results with statistical signiﬁcance (p < 0.05) are typed in bold.
FeNO, fractional exhaled nitric oxide; CI, conﬁdence interval; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity.
onal exhaled nitric oxide in prolonged and chronic cough according to
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Fig. 3. The stacked bar chart with three categories of FeNO levels in the three groups of
patients with prolonged and chronic cough (N ¼ 105). As FeNO levels increase, the
proportion of patients with AC becomes higher. The category of FeNO level 58.4 ppb
was all occupied by patients with AC. However, 55% of subjects who had FeNO level
<29.2 ppb were also diagnosed as AC. Low FeNO: <29.2 ppb, Moderate FeNO:
29.2e58.4 ppb, High FeNO: 58.4 ppb. FeNO, fractional exhaled nitric oxide; CPA,
cough-predominant asthma; CVA, cough-variant asthma; NAC, non-asthmatic cough;
AC, asthmatic cough; ppb, parts per billion.
T. Asano et al. / Allergology International xxx (2016) 1e7 5Figure 3 shows the stacked bar chart of the three groups
stratiﬁed by FeNO levels; the cut-off value calculated by ROC curve
analysis (29.2 ppb) and its two-fold value (58.4 ppb) were used for
the stratiﬁcation. The proportion of AC subjects increased as FeNO
levels became higher. The category of high FeNO level (58.4 ppb)
was occupied by the AC group, which also accounted for 91% of the
intermediate FeNO level (29.2e58.4 ppb) category. However, up to
55% of the low FeNO level (<29.2 ppb) category belonged to the AC
group. Similar results were obtained when 25 ppb and 50 ppb
FeNO levels, which were proposed by the ofﬁcial American
Thoracic Society guidelines,28 were applied in the analysis (data
not shown).
FeNO levels signiﬁcantly correlated with blood eosinophil
counts (r ¼ 0.42, p < 0.0001), and serum total IgE titers (r ¼ 0.31,
p ¼ 0.002).Table 5
Previous studies on FeNO measurement in patients with prolonged and/or chronic coug
Author
[reference]
Category of
asthma (n)
Control
group (n)
Cut-off value (AUC/
Sensitivity/Speciﬁcity) case
(asthma) vs control
(non-asthma)
Coug
(wee
Shimoda [12] CA (92)
CVA (90)
HC (90) 20 ppb (NA/72/83)
CA vs HC
>8
Chatkin [15] AC (8)
CA (44)
NAC (30)
HC (22)
30 ppb (NA/75/87)
AC vs NAC
>3
Sato [16] CA (30)
CVA (18)
EB (8)
NAC (15)
38.8 ppb (NA/79/91)
(CA þ CVA) vs (EB þ NAC)
>3
Kowal [17] AC (178) NAC (362)
HC (100)
40 ppb (0.924/88/83)
AC vs NAC
>8
Fujimura [18] CA (10)
CVA (11)
Atopic cough (9) N.A. >8
Our study AC (77) NAC (28) (A) 29.2 ppb (0.74/60/89)
AC vs NAC (all subjects)
(B) 31.1 ppb (0.83/71/100)
AC vs NAC (atopic subjects)
(C) 19.9 ppb (0.65/59/77)
AC vs NAC (non-atopic
subjects)
>3
FeNO, fractional exhaled nitric oxide; ppb, parts per billion; AUC, area under the curve; C
cough; NAC, non-asthmatic cough; EB, eosinophilic bronchitis; N.A., not available.
Please cite this article in press as: AsanoT, et al., Diagnostic utility of fractio
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Our study conﬁrmed that measurement of FeNO levels was a
relevant diagnostic procedure for prolonged and chronic cough.We
showed that 91% of subjects with intermediate FeNO levels
(29.2e58.4 ppb), and all the subjects with high FeNO levels
(58.4 ppb) belonged to AC groups (Fig. 3). Therefore, the possi-
bility of AC as a cause of chronic cough becomes higher as FeNO
levels increase. Previous reports demonstrated that healthy vol-
unteers12,13,15,29,30 and NAC patients15e17 rarely had high FeNO
levels (50 ppb). Therefore, high FeNO levels (58.4 ppb) seem to
have high speciﬁcity for AC.
Nitric oxide has been implicated in the pathophysiology of
asthma.31 Since Th2-driven airway inﬂammation32,33 results in the
upregulation of inducible nitric oxide synthase (iNOS) in bronchial
epithelial cells, high FeNO levels have been observed in asth-
matics.9,10,34 Alongwith a signiﬁcant correlation between FeNO and
increased sputum eosinophils,8,35 FeNO is regarded as an indirect
marker of eosinophilic airway inﬂammation that is characteristic of
asthma28 and AC.36 Although a useful method for evaluating
eosinophilic airway inﬂammation, sputum induction is complex,
time-consuming, and carries the potential to induce bronchocon-
striction or pharyngeal discomfort. On the other hand, FeNO mea-
surements seem much more suitable for routine clinical practice
because it is less invasive and easier to perform.30
Previous reports12,15e18 and our present study of persistent
cough patients proposed different FeNO cut-off levels for dis-
tinguishing asthmatic subjects (classic asthma predominated by
wheezing, CPA, or CVA) from non-asthmatic subjects (healthy
control or NAC) (Table 5). Because all these studies consistently
used the chemiluminescence method for FeNO measurement, the
discrepancies of cut-off levels among these studies may be due to
different methods of selection of cases (category of asthma) and
control group (non-asthma or healthy control) and the varying
patients' characteristics. Although all studies were consistent in the
observation that FeNO measurement was a useful diagnostich, which consistently used the chemiluminescence method.
h duration
ks)
Entry of current s
moker
Major differences from our study
Included  Control subjects were all non-atopic.
 Higher prevalence of atopy in CA (87.0%)
Excluded  Expiratory ﬂow rate for measuring FeNO was
45 ml/s, not 50 ml/s.
 AC were all atopic (100%).
Included  Difference of control groups.
 Sputum eosinophilia (3%) was included in
the criteria of CA and CVA.
Excluded  All subjects were young adults aged < 45
years old.
 Prevalence of atopy in each subgroups was
not described.
 Median FeNO levels in AC was higher
(86 ppb) compared with our study.
N.A.  No cut-off levels were proposed.
Excluded e
A, classical asthma; CVA, cough variant asthma; HC, healthy control; AC, asthmatic
nal exhaled nitric oxide in prolonged and chronic cough according to
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T. Asano et al. / Allergology International xxx (2016) 1e76procedure for prolonged or chronic cough, none took notice of AC
patients with low FeNO levels. Our present study revealed that 40%
of AC patients accounted for 55% of the patients in the low FeNO
level (<29.2 ppb) category. Since FeNO is considered as a surrogate
marker of eosinophilic airway inﬂammation, our results were
compatible with the previous report which revealed the prevalence
of eosinophilic inﬂammation (sputum eosinophil >3%) in asth-
matics (35e46%).37,38 These results implied a need to reconsider
that about half of patients with AC have low FeNO levels. Namely, a
low FeNO level cannot rule out the possibility of AC (Fig. 1 and 3,
Table 3).
The difference in FeNO levels between CPA or classic asthma and
CVA seems controversial. Although our study and that by Shimoda
et al.12 demonstrated these signiﬁcant differences, other reports
reported otherwise.15,39 Since a degree of mucosal and bron-
choalveolar eosinophilia between classic asthma and CVA are
similar,40 there is a possibility that varying inﬂuences of con-
founding factors, such as atopic status41 (although not signiﬁcant in
the present study), and disease severity may have affected the
results.
Several factors may affect the validity of FeNOmeasurements. In
classic asthma, Matsunaga et al. proposed that FeNO levels should
be evaluated while considering the inﬂuence of allergic rhinitis and
smoking.11 In our study, the effects of medications (inhaled corti-
costeroids42 and anti-leukotriene agents43) and smoking44 were
excluded at study entry. In this study, atopic status and diagnosis
were independent determinants of FeNO levels in patients with
prolonged and chronic cough. Previous studies also revealed that
atopy itself is responsible for elevated FeNO levels even among
subjects without asthma or lower airway symptoms,45e47 which
may lead to misdiagnosis of asthma. Therefore, taking atopic status
into account seemed to be inevitable when evaluating FeNO levels
in prolonged and chronic cough. Although some reports including
ours revealed a correlation between FeNO level and non-speciﬁc
IgE titer,12,16 more applicable measures are required in clinical
practice. Therefore, we proposed cut-off levels based on atopic
status. Our results implied the necessity of applying two cut-off
levels based on atopic status in the evaluation of prolonged and
chronic cough. In addition, FeNO measurement may be less useful
in non-atopic subjects than in atopic subjects. To the best of our
knowledge, this study was the ﬁrst to propose different cut-off
levels to discriminate AC from NAC based on atopy.
AC is a major cause of prolonged and chronic cough in Japan.1,48
Although the prevalence of AC in our study (73.3%) seemed higher
than those of the US (15e43%), UK (10e26%),48 and other previous
reports in Japan (44e57%),4,5,49,50 it was similar to a recent multi-
center study in Japan (70.6%).1 Different medical systems, as well as
geographical issues and routine diagnostic procedures, might ac-
count for this discrepancy. That is, the medical system in Japan,
which allows patients to visit specialist clinics on ﬁrst consult,48
may have contributed to the high prevalence of treatment-naive
AC patients in this study. Additionally, our method of classifying
overlapping cases of AC with various causes of NAC to AC subgroups
(CPA or CVA) (Table 1) and our inclusion criteria, including patients
with shortness of breath or wheezing, might have strengthened
this trend.
This study was limited by its retrospective design, which failed
to ascertain the presence or absence of allergic rhinitis. Neverthe-
less, we consecutively recruited patients using a consistent protocol
that included spirometry, IgE, and FeNO measurements. Never-
theless, future prospective studies are awaited to reinforce our
results.
In summary, FeNO levels were signiﬁcantly higher in patients
with AC than in those with NAC. Although FeNO measurement is
useful in the differential diagnosis of prolonged and chronic choughPlease cite this article in press as: AsanoT, et al., Diagnostic utility of fracti
atopic status, Allergology International (2016), http://dx.doi.org/10.1016/for patients with atopy, its utility for those without atopy seems
limited. Intermediate to high FeNO levels might be applicable for
the diagnosis of AC, but low FeNO levels do not exclude the diag-
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